More News

07 Mar 2018 Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
07 Mar 2018 CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS
07 Mar 2018 Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
06 Mar 2018 Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina
06 Mar 2018 Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets
06 Mar 2018 Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates
01 Mar 2018 C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic Genomics
01 Mar 2018 Heidelberg Pharma Signs License Agreement with The University of Texas MD Anderson Cancer Center
01 Mar 2018 Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
28 Feb 2018 Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
28 Feb 2018 MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
27 Feb 2018 Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases
27 Feb 2018 Beacon Discovery announces multi-year GPCR drug discovery collaboration with Takeda focused on gastrointestinal disorders
27 Feb 2018 Dyadic International, Inc. Announces Research and Development Collaboration with Mitsubishi Tanabe Pharma Corporation To Produce Two Target Proteins in C1
22 Feb 2018 Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
21 Feb 2018 Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline
21 Feb 2018 Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists
20 Feb 2018 Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics
20 Feb 2018 Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca
20 Feb 2018 Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
20 Feb 2018 Amunix announces XTEN® and ProTIA technology licensing agreement with Celgene
20 Feb 2018 Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
20 Feb 2018 Zealand Pharma and UniQuest collaborate to develop novel drug candidates for gastrointestinal diseases
18 Feb 2018 Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
15 Feb 2018 Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up